Overview

We are focused on leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small and large molecule drugs to help people impacted by underserved immuno-inflammatory conditions.

Our team of experienced and accomplished scientists use the proprietary KINect^® technology platform to create new small molecule medicines through kinome innovation. We are exploring the kinome, a subset of the human genome that consists of a collection of 518 protein kinases, one of the largest of all human gene families, responsible for signal transduction controlling cellular responses. We’re focused on novel approaches toward the design and development of kinase inhibitors that target key enzymes involved in chronic inflammation, autoimmune disease, and the regulation of cancer growth, survival and metastasis.

Our scientists are also developing innovative biologic product candidates such as monoclonal and bispecific antibodies incorporating novel mechanisms and dual-targeting strategies to target validated pathways and proteins involved in modulating important immune-inflammatory diseases. By pursuing both traditional monoclonal antibodies and innovative bispecific approaches, we aim to develop differentiated biological therapies that address significant unmet needs in immuno-inflammatory diseases.

Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization.. Confluence serves as a research partner for pharma and biotech companies across therapeutic areas and gene families. Confluence’s expertise includes cell and molecular biology, biochemistry, enzymology, biomarker development, immunology and inflammation, in vivo efficacy models, bioanalytical, computational and medicinal chemistry. To learn more, visit www.confluencediscovery.com.